Insights into Readmission Trends Following Inpatient Chemotherapy for Acute Lymphoblastic Leukemia: A 30- Day Analysis

Silpa C1*, Diana Z1, Anthony Y1 and Miguel G2

1Department of Internal Medicine, Creighton University School of Health Science, AZ, USA
2Department of Hematology Oncology, St. Joseph Medical center, AZ, USA

^*Correspondance to: Silpa Choday 

 PDF  Full Text Research Article | Open Access

Abstract:

Introduction: Acute Lymphoblastic Leukemia (ALL) has significant morbidity due to its aggressive course and intensive treatment protocols. Understanding the patterns of readmission after inpatient chemotherapy is crucial for optimizing patient care and resource allocation. Methods: National Readmission Database is used to identify ALL patients who underwent inpatient chemotherapy between 2016 and 2020. Multivariable Logistic regression has been used. Results: A total of 22,483 admissions were analyzed. Of these, 72.5% (16,294) experienced readmission. Notably, the trend in readmission rates declined between 2016-2020, dropping from 76.1% to 66.3%. Among the 16,294 readmissions, 3,607 achieved remissions, 10,637 has stable disease and 2,051 had relapsed disease (P<0.001). The mean age at remission was at 18.9 years, while non-remission and relapse occurred at older ages (32.2 and 31 years, respectively, P<0.001). In terms of insurance, private insurance had the highest readmission rate at 48%, followed by Medicaid at 35%, and Medicare at 12% (P<0.001). The odds ratios indicated significant differences: Elective readmissions had a significantly higher risk compared to non-elective readmissions (4.01, 95% CI 3.44-4.67, P<0.001). Additionally, patients achieving remission had a lower risk of readmission compared to those not achieving remission (0.52, 95% CI 0.42-0.64, P=0.003), and. relapse (0.52, 95% CI 0.42-0.64, P<0.001). Conclusion: Our study highlights factors such as relapsed disease, insurance status, elective admissions, and age were associated with higher readmission risk. These findings emphasize the importance of targeted interventions to reduce the rates of readmission and improve outcomes in ALL patients.

Keywords:

Acute Lymphoblastic Leukemia; Remission; Readmissions; Inpatient chemotherapy; NRD

Cite the Article:

Silpa C, Diana Z, Anthony Y, Miguel G. Insights into Readmission Trends Following Inpatient Chemotherapy for Acute Lymphoblastic Leukemia: A 30-Day Analysis. Ann Clin Case Rep. 2024; 9: 2673.